When high-dose isoniazid is considered as part of MDR-TB treatment but the mutation conferring isoniazid resistance is unknown, the local epidemiology of isoniazid resistance mutations should be considered (high-level isoniazid resistance is conferred by the katG mutation and lower level resistance by the inhA mutations) [46]. The gene discussed is INHA; the disease is tuberculosis.